CD4 and neoplasm: Anti‐mouse CLEC9A Abs are as effective as anti‐mouse DEC‐205 Abs at delivering Ags to murine cDC1s in vivo to prime CD8+ T‐cell responses,46 as well as humoral and CD4+ T‐cell responses, which collectively mediate protective tumor‐specific immunity.41, 42